MedTrace Logo

Contrast-Enhanced Mammography for Breast Cancer Staging in Patients Referred for a Second Opinion

NCT05036083 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2025-09-17

Study results available
· View outcomes & findings →

Summary

This clinical trial investigates contrast-enhanced mammography (CEM) in detecting breast cancer. CEM is similar to standard mammography, but it includes an injection of an iodine-based contrast, which makes tissue and blood vessels more visible in scans. Diagnostic procedures, such as CEM, may increase the chance of finding breast cancers and decrease the risk of having unnecessary biopsies.

Conditions

  • Breast Carcinoma
  • Invasive Breast Carcinoma

Interventions

PROCEDURE

Contrast-Enhanced Mammography

Undergo CEM

PROCEDURE

Digital Tomosynthesis Mammography

Undergo DBT

OTHER

Electronic Health Record Review

Medical records reviewed

DRUG

Iodinated Contrast Agent

Given IV

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Olena Weaver · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-19
Primary Completion
2024-03-25
Completion
2024-03-25
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05036083 on ClinicalTrials.gov